Funding for this research was provided by:
Michael Smith Foundation for Health Research (N/A)
Received: 9 November 2019
Accepted: 25 May 2020
First Online: 1 June 2020
Ethics approval and consent to participate
: Ethics approval and patient consent was obtained (UBC-PHC REB H16–01164).
: All authors have approved the submission and provide consent to publish.
: B.S.Q has received consulting fees from Vertex Pharmaceuticals and advisory board fees from Proteostasis Therapeutics.